Treatment
Pembrolizumab clinical trials
We’re tracking 615 recruiting studies that include Pembrolizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06113809RecruitingPhase 1
Palbociclib and pembrolizumab for advanced sarcoma
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
Iowa City, IowaAges 12 years+ - NCT06123338RecruitingPhase 2
Pembrolizumab plus chemo and trastuzumab for HER2+ stomach cancer
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Boston, MassachusettsAges 18 years+ - NCT06157151RecruitingPhase 2
New drug plus pembrolizumab for advanced cervical cancer
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
Little Rock, ArkansasAges 18 years+ - NCT06160843RecruitingPhase 2
Pembrolizumab and olaparib for relapsed peripheral T-cell lymphoma
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
SingaporeAges 21–99 - NCT06161545RecruitingPhase 2
Immunotherapy before surgery for head and neck cancer
This trial tests whether giving a combination of immunotherapy drugs (pembrolizumab, N-803, and possibly PD-L1 t-haNK cells) before surgery can help treat head and neck cancer that has not been treated yet. It is for people whose cancer is p16-negative (a specific marker) and is at an intermediate or high risk of coming back.
Bethesda, MarylandAges 18–120 - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+ - NCT06216301RecruitingPhase 3
Electric fields with immunotherapy and chemo for advanced lung cancer
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT06236438RecruitingPhase 2/Phase 3
Livmoniplimab plus budigalimab and chemo for untreated lung cancer
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06246968RecruitingPhase 1
Pembrolizumab and Cryoablation for Breast Cancer
This trial is testing a combination of a freezing procedure (cryoablation) and an immunotherapy drug called pembrolizumab (Keytruda) for people with triple-negative breast cancer that has spread. The goal is to see if freezing the tumor helps the immune system fight the cancer better.
Basking Ridge, New JerseyAges 18 years+ - NCT06253494RecruitingPhase 1/Phase 2
Combination therapy trial for advanced endometrial cancer
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
Bethesda, MarylandAges 18–120 - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06302569RecruitingPhase 2
Pembrolizumab plus enfortumab vedotin for rare kidney cancers
This trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and enfortumab vedotin (a targeted therapy)—for people with collecting duct carcinoma or renal medullary carcinoma, two rare types of kidney cancer that have spread. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
MilanAges 18 years+ - NCT06304350RecruitingPhase 2
Pembrolizumab plus chemo before surgery for esophageal cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+ - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Little Rock, ArkansasAges 18 years+ - NCT06345729RecruitingPhase 3
Study of Calderasib and Pembrolizumab for Advanced Lung Cancer
This trial tests a new combination of two drugs (Calderasib and Pembrolizumab) in people with a specific type of advanced lung cancer (non-small cell lung cancer) that has a KRAS G12C mutation and high PD-L1 levels. It aims to see if this treatment can help shrink or control the cancer.
Bakersfield, CaliforniaAges 18 years+ - NCT06353906RecruitingPhase 2
Chemo plus immunotherapy for advanced penile cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
LeuvenAges 18 years+ - NCT06353997RecruitingPhase 2
New immunotherapy combination before surgery for triple-negative breast cancer
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT06374602RecruitingPhase 2
Pembrolizumab and lenvatinib for anaplastic thyroid cancer
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
Saint PetersburgAges 18 years+ - NCT06439836RecruitingPhase 1
Combination immunotherapy for advanced bladder cancer
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Duarte, CaliforniaAges 18 years+ - NCT06470282RecruitingPhase 1/Phase 2
Drug combo plus radiation for muscle-invasive bladder cancer
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
San Francisco, CaliforniaAges 18 years+ - NCT06475235RecruitingPhase 1
Pembrolizumab with chemo for new CNS lymphoma
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
Boston, MassachusettsAges 18 years+
Common questions
- Are there clinical trials studying Pembrolizumab?
- Yes. Clin2 currently lists 615 recruiting studies that include Pembrolizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pembrolizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pembrolizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pembrolizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.